Merck’s KEYTRUDA (pembrolizumab) has become the first PD‑1 inhibitor to show a statistically significant and clinically meaningful improvement in progression‑free survival (PFS) as monotherapy over platinum doublet chemotherapy in the first‑line setting for patients with mismatch repair‑deficient (dMMR) advanced or recurrent endometrial cancer, based on the Phase .
KEYTRUDA is now the first and only PD‑1 inhibitor approved as monotherapy in this frontline dMMR endometrial cancer population, offering a potential chemo‑free option.
This win builds on KEYTRUDA’s established role in endometrial cancer, including prior approvals in combination with chemotherapy (KEYNOTE‑868/NRG‑GY018) and with LENVIMA (lenvatinib) for advanced or recurrent disease.
Sources:
KEYTRUDA® (pembrolizumab) as Monotherapy ...
Merck's KEYTRUDA® (pembrolizumab) Receives 30th ...
FDA Approves Merck's KEYTRUDA® (pembrolizumab) ...
KEYTRUDA® (pembrolizumab) Plus LENVIMA® ...
FDA Approves Merck's KEYTRUDA® (pembrolizumab) ...
FDA approves pembrolizumab with chemotherapy for ...
Merck Advances Oncology Innovation, Highlighting ...
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval
Once conditional, Merck's Keytruda, Eisai's Lenvima win full approval for endometrial cancer
FDA Approves Two First-Line Immunotherapies for ...
FDA approves Keytruda combination for primary advanced ...
Jemperli contends with blockbuster Keytruda in ...
FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Patients ...